Background Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and
have shown benefit in the treatment of metastatic colorectal cancer, whether used as single …

Over the past 10 years there has been a significant increase in the armamentarium of agents
available for use in the treatment of advanced colorectal cancer (CRC). Among these new …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Although significant advances have been made in the treatment of metastatic colorectal
cancer (CRC), prognosis remains poor, with a 5-year survival of less than 10%. Monoclonal …

Learning Objectives After completing this course, the reader will be able to: Describe the
activity of EGFR inhibitors in metastatic colorectal cancer. Discuss planned studies. Discuss …

Background Head-to-head trials comparing first-line epidermal growth factor receptor
inhibitor (EGFRI) versus vascular endothelial growth factor inhibitor (bevacizumab) therapy …

More therapeutic options are now available than ever before for patients with metastatic
colorectal cancer (mCRC) and, as such, treatment decisions have become more complex. A …

Background. Survival of patients with metastatic colorectal cancer (mCRC) has been
significantly improved with the introduction of the monoclonal antibodies targeting the …

Despite the introduction of newer chemotherapeutic agents such as irinotecan, capecitabine
and oxaliplatin, patients with metastatic colorectal cancer (mCRC) still have a poor …

Metastatic colorectal cancer is the fourth most common cause of death due to cancer after
those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting …